Vaikom Mahadevan, MD

Cardiologist

Dr. Vaikom Mahadevan is a global leader in interventional cardiology for the treatment of adult congenital heart disease (ACHD) and structural heart disease. He has extensive experience performing adult congenital and transcatheter valvar interventions, including implantation of transcatheter valves in all four positions in the heart. He also has a strong interest in intracardiac echo imaging of the heart.

Before joining UCSF, Mahadevan served as a consultant cardiologist and interventionist at the Manchester Royal Infirmary, Central Manchester University Hospitals. In Manchester, he was director of the ACHD and transcatheter aortic valve replacement program, as well as director of the ACHD Interventional program for northwestern England. He also established and led the adult congenital pulmonary hypertension service for this region.

Mahadevan earned his medical degree from Stanley Medical College in Chennai, India, and received further training in internal medicine and cardiology in the U.K. He completed a fellowship in adult congenital heart disease and intervention at the Royal Brompton Hospital, London, followed by a fellowship in the same specialties at Toronto General Hospital in Ontario, Canada.

His clinical research interests include adult congenital and transcatheter valve implantation and pulmonary hypertension in ACHD. Mahadevan is a professor of medicine at UCSF.

Clinics

Congenital Heart Disease Clinic
535 Mission Bay Blvd. South
San Francisco, CA 94158
Phone: (415) 353-2873
Fax: (415) 353-2528

Hours: Monday to Friday
8:00 a.m. – 4:30 p.m.

Academic Title

Professor

More about Vaikom Mahadevan

Education

Stanley Medical College 1994

Residencies

Doncaster 1997

Fellowships

Royal Brompton Hospital, Adult Congenital Heart Disease and Intervention 2004
Toronto General Hospital, Adult Congenital Heart Disease and Intervention 2005

Selected Research and Publications

  1. Guerrero M, Urena M, Himbert D, Wang DD, Eleid M, Kodali S, George I, Chakravarty T, Mathur M, Holzhey D, Pershad A, Fang HK, O'Hair D, Jones N, Mahadevan VS, Dumonteil N, Rodés-Cabau J, Piazza N, Ferrari E, Ciaburri D, Nejjari M, DeLago A, Sorajja P, Zahr F, Rajagopal V, Whisenant B, Shah PB, Sinning JM, Witkowski A, Eltchaninoff H, Dvir D, Martin B, Attizzani GF, Gaia D, Nunes NSV, Fassa AA, Kerendi F, Pavlides G, Iyer V, Kaddissi G, Witzke C, Wudel J, Mishkel G, Raybuck B, Wang C, Waksman R, Palacios I, Cribier A, Webb J, Bapat V, Reisman M, Makkar R, Leon M, Rihal C, Vahanian A, O'Neill W, Feldman T. 1-Year Outcomes of Transcatheter Mitral Valve Replacement in Patients With Severe Mitral Annular Calcification. J Am Coll Cardiol. 2018 May 01; 71(17):1841-1853.
  2. Marcus SG, Mahadevan VS, Deuse T. Hybrid Open Minimally-Invasive Transcatheter Mitral Valve Replacement. Ann Thorac Surg. 2018 Mar 29.
  3. Lee A, Mahadevan VS, Gerstenfeld EP. Iatrogenic atrial septal defect with right-to-left shunt following atrial fibrillation ablation in a patient with arrhythmogenic right ventricular cardiomyopathy. HeartRhythm Case Rep. 2018 Apr; 4(4):159-162.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.